|
CBMG expansion to boost clinical trial capacity
May 2017
SHARING OPTIONS:
SHANGHAI, China & CUPERTINO, Calif.—Cellular Biomedicine Group Inc. (CBMG) has completed its newly expanded 30,000-square-foot facility
in Huishan High Tech Park in Wuxi, China. An expected 20,000 square feet of the Wuxi GMP facility will be used for advanced stem cell culturing, centralized
plasmid and viral vector production, cell banking and reagent development. The company believes that this facility, together with its Zhangjiang Shanghai and
Beijing GMP facilities, will be able to support simultaneous clinical trials for five different CAR-T and stem cell products, or have the capacity to treat
up to 10,000 cancer and 10,000 knee osteoarthritis patients annually.
Tony (Bizuo) Liu, CEO of CBMG, remarked that “We
will now be able to centralize, standardize and automate our manufacturing capabilities fully in-house while enhancing our capacity to meet the production
demands of multiple products in development as part of our overall chemistry, manufacturing and controls process.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|